Models, mechanisms and clinical evidence for cancer dormancy

Nature Reviews Cancer

Volumn 7, Issue 11, 2007, Pages 834-846

  Aguirre Ghiso, Julio A ^a  

^a STATE UNIVERSITY OF NEW YORK   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FOCAL ADHESION KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PLATELET DERIVED GROWTH FACTOR; PROTEIN BAX; UROKINASE; VASCULOTROPIN;

ANGIOGENESIS; CANCER GROWTH; CELL MATURATION; CLINICAL FEATURE; DRUG RESISTANCE; HUMAN; IMMUNE SYSTEM; IMMUNOSURVEILLANCE; LATENT PERIOD; METASTASIS; MICROENVIRONMENT; ONCOGENE NEU; ONCOGENE RAS; PRIORITY JOURNAL; RECURRENT CANCER; REVIEW; TUMOR GROWTH; TUMOR MODEL;

ANIMALS; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; EPIGENESIS, GENETIC; HUMANS; MICE; MICE, INBRED STRAINS; MICE, TRANSGENIC; MODELS, BIOLOGICAL; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM, RESIDUAL; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; TIME FACTORS; TUMOR BURDEN; TUMOR ESCAPE;

EID: 35548936833     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc2256     Document Type: Review

References (140)

1. Pantel, K. & Brakenhoff, R. H. Dissecting the metastatic cascade. Nature Rev. Cancer 4, 448-456 (2004).
2. Schmidt-Kittler, O. et al. From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression. Proc. Natl Acad. Sci. U S A 100, 7737-7742 (2003). First evidence that breast cancer cells can disseminate in a far less progressed genomic state than previously thought. Genomic aberrations that make them metastatic are acquired after this step.
3. Karrison, T. G., Ferguson, D. J. & Meier, P. Dormancy of mammary carcinoma after mastectomy. J. Natl Cancer Inst. 91, 80-85 (1999).
4. Pfitzenmaier, J. et al. Telomerase activity in disseminated prostate cancer cells. BJU Int. 97, 1309-1313 (2006).
5. Weckermann, D. et al. Disseminated cytokeratin positive tumor cells in the bone marrow of patients with prostate cancer: detection and prognostic value. J. Urol. 166, 699-703 (2001).
6. Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57-70 (2000).
7. Talmadge, J. E., Wolman, S. R. & Fidler, I. J. Evidence for the clonal origin of spontaneous metastases. Science 217, 361-363 (1982). First evidence that spontaneous metastases are clonal in origin and that they probably are derived from different progenitor cells.
8. Schardt, J. A. et al. Genomic analysis of single cytokeratin-positive cells from bone marrow reveals early mutational events in breast cancer. Cancer Cell 8, 227-239 (2005). This paper genetically characterized disseminated single breast tumour cells and determined that cells with normal karyotypes can disseminate, suggesting that dissemination might occur very early.
9. Demicheli, R. Tumour dormancy: findings and hypotheses from clinical research on breast cancer. Semin. Cancer Biol. 11, 297-306 (2001).
10. Chambers, A. F., Groom, A. C. & MacDonald, I. C. Dissemination and growth of cancer cells in metastatic sites. Nature Rev. Cancer 2, 563-572 (2002).
11. Heyn, C. et al. In vivo MRI of cancer cell fate at the single-cell level in a mouse model of breast cancer metastasis to the brain. Magn. Reson. Med. 56, 1001-1010 (2006).
12. Klein, C. A. & Hölzel, D. Systemic cancer progression and tumor dormancy: mathematical models meet single cell genomics. Cell Cycle 5, 1788-1798 (2006).
13. Lacroix, M. Significance, detection and markers of disseminated breast cancer cells. Endocr. Relat. Cancer 13, 1033-1067 (2006).
14. Kovacs, A. F., Ghahremani, M. T., Stefenelli, U. & Bitter, K. Postoperative chemotherapy with cisplatin and 5-fluorouracil in cancer of the oral cavity and the oropharynx - long-term results. J. Chemother. 15, 495-502 (2003).
15. Boudreau, N. & Bissell, M. J. Extracellular matrix signaling: integration of form and function in normal and malignant cells. Curr. Opin. Cell Biol. 10, 640-646 (1998).
16. Wicha, M. S. Cancer stem cells and metastasis: lethal seeds. Clin. Cancer Res. 12, 5606-5607 (2006).
17. Kaplan, R. N., Rafii, S. & Lyden, D. Preparing the "soil": the premetastatic niche. Cancer Res. 66, 11089-11093 (2006).
18. Aguirre-Ghiso, J. A., Ossowski, L. & Rosenbaum, S. K. Green fluorescent protein tagging of extracellular signal-regulated kinase and p38 pathways reveals novel dynamics of pathway activation during primary and metastatic growth. Cancer Res. 64, 7336-7345 (2004). Provides evidence that spontaneous or forced downregulation of uPAR induces a state of tumor cell dormancy through decreased ERK signalling and G0-G1 arrest.
19. Aguirre Ghiso, J. A., Kovalski, K. & Ossowski, L. Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling. J. Cell Biol. 147, 89-104 (1999).
20. White, D. E. et al. Targeted disruption of β1-integrin in a transgenic mouse model of human breast cancer reveals an essential role in mammary tumor induction. Cancer Cell 6, 159-170 (2004). Provides evidence that mouse mammary epithelial cells transformed with an oncogene require β1 integrin for tumour progression. Absence of this integrin results in a state of tumour cell dormancy.
21. Weaver, V. M. et al. Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies. J. Cell Biol. 137, 231-245 (1997). Provides evidence that correcting the crosstalk between the tumour cell and the microenvironment can result in loss of malignancy associated with a more differentiated phenotype.
22. Liu, D., Aguirre Ghiso, J., Estrada, Y. & Ossowski, L. EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma. Cancer Cell 1, 445-457 (2002). Shows that loss of uPAR expression causes tumour cell dormancy by impairing EGFR activation by integrins that transduce mitogenic signals from the extracellular matrix molecule fibronectin.
23. Aguirre Ghiso, J. A. Inhibition of FAK signaling activated by urokinase receptor induces dormancy in human carcinoma cells in vivo. Oncogene 21, 2513-2524 (2002).
24. Aguirre-Ghiso, J. A., Liu, D., Mignatti, A., Kovalski, K. & Ossowski, L. Urokinase receptor and fibronectin regulate the ERK(MAPK) to p38(MAPK) activity ratios that determine carcinoma cell proliferation or dormancy in vivo. Mol. Biol. Cell 12, 863-879 (2001).
25. Aguirre-Ghiso, J. A., Estrada, Y., Liu, D. & Ossowski, L. ERK(MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38(SAPK). Cancer Res. 63, 1684-1695 (2003).
26. Ranganathan, A. C., Zhang, L., Adam, A. P. & Aguirre-Ghiso, J. A. Functional coupling of p38-induced up-regulation of BiP and activation of RNA-dependent protein kinase-like endoplasmic reticulum kinase to drug resistance of dormant carcinoma cells. Cancer Res. 66, 1702-1711 (2006).
27. Bulavin, D. V. & Fornace, A. J., Jr. p38 MAP kinase's emerging role as a tumor suppressor. Adv. Cancer Res. 92, 95-118 (2004).
28. Heiss, M. M. et al. Individual development and uPAreceptor expression of disseminated tumour cells in bone marrow: a reference to early systemic disease in solid cancer. Nature Med. 1, 1035-1039 (1995). Shows that patients with tumour relapse had an increase or higher number of disseminated tumour cells in bone marrow aspirates, whereas patients without recurrence had negative or low tumour cell counts. uPAR expression on disseminated tumour cells was correlated with increasing tumour cell counts and poor prognosis.
29. Gattelli, A. et al. Progression of pregnancy-dependent mouse mammary tumors after long dormancy periods. Involvement of Wnt pathway activation. Cancer Res. 64, 5193-5199 (2004).
30. Gattelli, A., Zimberlin, M. N., Meiss, R. P., Castilla, L. H. & Kordon, E. C. Selection of early-occurring mutations dictates hormone-independent progression in mouse mammary tumor lines. J. Virol. 80, 11409-11415 (2006).
31. Naumov, G. N. et al. Cellular expression of green fluorescent protein, coupled with high-resolution in vivo videomicroscopy, to monitor steps in tumor metastasis. J. Cell Sci. 112 (Pt 12), 1835-1842 (1999).
32. Naumov, G. N. et al. Persistence of solitary mammary carcinoma cells in a secondary site: a possible contributor to dormancy. Cancer Res. 62, 2162-2168 (2002). This paper used an experimental model to show that solitary dormant cells that persist in target organs might be the source of dormancy and recurrence.
33. Steeg, P. S. Metastasis suppressors alter the signal transduction of cancer cells. Nature Rev. Cancer 3, 55-63 (2003).
34. Steeg, P. S., Ouatas, T., Halverson, D., Palmieri, D. & Salerno, M. Metastasis suppressor genes: basic biology and potential clinical use. Clin. Breast Cancer 4, 51-62 (2003).
35. Mehlen, P. & Puisieux, A. Metastasis: a question of life or death. Nature Rev. Cancer 6, 449-458 (2006).
36. Bandyopadhyay, S. et al. Interaction of KAI1 on tumor cells with DARC on vascular endothelium leads to metastasis suppression. Nature Med. 12, 933-938 (2006).
37. Rinker-Schaeffer, C. W., O'Keefe, J. P., Welch, D. R. & Theodorescu, D. Metastasis suppressor proteins: discovery, molecular mechanisms, and clinical application. Clin. Cancer Res. 12, 3882-3889 (2006).
38. Hickson, J. A. et al. The p38 kinases MKK4 and MKK6 suppress metastatic colonization in human ovarian carcinoma. Cancer Res. 66, 2264-2270 (2006).
39. Kauffman, E. C., Robinson, V. L., Stadler, W. M., Sokoloff, M. H. & Rinker-Schaeffer, C. W. Metastasis suppression: the evolving role of metastasis suppressor genes for regulating cancer cell growth at the secondary site. J. Urol. 169, 1122-1133 (2003).
40. Nash, K. T. et al. Requirement of KISS1 secretion for multiple organ metastasis suppression and maintenance of tumor dormancy. J. Natl Cancer Inst. 99, 309-321 (2007). First evidence that a metastasis suppressor gene functions though the induction of dormancy.
41. Vander Griend, D. J. et al. Suppression of metastatic colonization by the context-dependent activation of the c-Jun NH2-terminal kinase kinases JNKK1/MKK4 and MKK7. Cancer Res. 65, 10984-10991 (2005).
42. Nakayama, K. et al. Homozygous deletion of MKK4 in ovarian serous carcinoma. Cancer Biol. Ther. 5, 630-634 (2006).
43. Xia, Z., Dickens, M., Raingeaud, J., Davis, R. J. & Greenberg, M. E. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 270, 1326-1331 (1995).
44. Ranganathan, A. C., Adam, A. P., Zhang, L. & Aguirre-Ghiso, J. A. Tumor cell dormancy induced by p38(SAPK) and ER-stress signaling: an adaptive advantage for metastatic cells? Cancer Biol. Ther. 5, 729-735 (2006).
45. Hunter, K. Host genetics influence tumour metastasis. Nature Rev. Cancer 6, 141-146 (2006).
46. Crawford, N. P. et al. Germline polymorphisms in SIPA1 are associated with metastasis and other indicators of poor prognosis in breast cancer. Breast Cancer Res. 8, R16 (2006).
47. Park, Y. G. et al. Sipa1 is a candidate for underlying the metastasis efficiency modifier locus Mtes1. Nature Genet. 37, 1055-1062 (2005). Provides evidence that constitutional genetic polymorphisms in a gene can affect tumour metastasis.
48. Semenza, G. L. Targeting HIF-1 for cancer therapy. Nature Rev. Cancer 3, 721-732 (2003).
49. Folkman, J. Role of angiogenesis in tumor growth and metastasis. Semin. Oncol. 29, 15-18 (2002).
50. Naumov, G. N., Akslen, L. A. & Folkman, J. Role of angiogenesis in human tumor dormancy: animal models of the angiogenic switch. Cell Cycle 5, 1779-1787 (2006).
51. Bergers, G. & Benjamin, L. E. Tumorigenesis and the angiogenic switch. Nature Rev. Cancer 3, 401-410 (2003).
52. Naumov, G. N. et al. A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype. J. Natl Cancer Inst. 98, 316-325 (2006).
53. Watnick, R. S., Cheng, Y. N., Rangarajan, A., Ince, T. A. & Weinberg, R. A. Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis. Cancer Cell 3, 219-231 (2003).
54. Volpert, O. V. & Alani, R. M. Wiring the angiogenic switch: Ras, Myc, and Thrombospondin-1. Cancer Cell 3, 199-200 (2003).
55. Okajima, E. & Thorgeirsson, U. P. Different regulation of vascular endothelial growth factor expression by the ERK and p38 kinase pathways in v-ras, v-raf, and v-myc transformed cells. Biochem. Biophys. Res. Commun. 270, 108-111 (2000).
56. Guba, M. et al. A primary tumor promotes dormancy of solitary tumor cells before inhibiting angiogenesis. Cancer Res. 61, 5575-5579 (2001).
57. Giuriato, S. et al. Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch. Proc. Natl Acad. Sci. USA 103, 16266-16271 (2006).
58. Indraccolo, S. et al. Interruption of tumor dormancy by a transient angiogenic burst within the tumor microenvironment. Proc. Natl Acad. Sci. USA 103, 4216-4221 (2006).
59. Ruegg, C. & Mutter, N. Anti-angiogenic therapies in cancer: achievements and open questions. Bull. Cancer 94, 753-762 (2007).
60. Holmgren, L., O'Reilly, M. S. & Folkman, J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nature Med. 1, 149-153 (1995). Shows in a mouse model that the balance between apoptosis and mitosis caused by lack of vascularization can induce angiogenic dormancy.
61. Al-Mehdi, A. B. et al. Intravascular origin of metastasis from the proliferation of endothelium-attached tumor cells: a new model for metastasis. Nature Med. 6, 100-102 (2000). Shows in a mouse model that disseminated tumour cells can start growing intravascularly into metastases, bypassing any initial need for blood vessels.
62. Pantel, K. & Otte, M. Disseminated tumor cells: diagnosis, prognostic relevance, and phenotyping. Recent Results Cancer Res. 158, 14-24 (2001).
63. Finn, O. J. Human tumor antigens, immunosurveillance, and cancer vaccines. Immunol. Res. 36, 73-82 (2006).
64. Weinhold, K. J., Miller, D. A. & Wheelock, E. F. The tumor dormant state. Comparison of L5178Y cells used to establish dormancy with those that emerge after its termination. J. Exp. Med. 149, 745-757 (1979).
65. Zou, W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nature Rev. Cancer 5, 263-274 (2005).
66. Weinhold, K. J., Goldstein, L. T. & Wheelock, E. F. The tumor dormant state. Quantitation of L5178Y cells and host immune responses during the establishment and course of dormancy in syngeneic DBA/2 mice. J. Exp. Med. 149, 732-744 (1979).
67. Matsuzawa, A., Takeda, Y., Narita, M. & Ozawa, H. Survival of leukemic cells in a dormant state following cyclophosphamide-induced cure of strongly immunogenic mouse leukemia (DL811). Int. J. Cancer 49, 303-309 (1991).
68. Rabinovsky, R., Uhr, J. W., Vitetta, E. S. & Yefenof, E. Cancer dormancy: lessons from a B cell lymphoma and adenocarcinoma of the prostate. Adv. Cancer Res. 97, 189-202 (2007).
69. + T cells and IFN-g in establishing and maintaining the tumor-dormant state. J. Immunol. 162, 2842-2849 (1999).
70. Saudemont, A. & Quesnel, B. In a model of tumor dormancy, long-term persistent leukemic cells have increased B7-H1 and B7.1 expression and resist CTL-mediated lysis. Blood 104, 2124-2133 (2004).
71. Mahnke, Y. D., Schwendemann, J., Beckhove, P. & Schirrmacher, V. Maintenance of long-term tumour-specific T-cell memory by residual dormant tumour cells. Immunology 115, 325-336 (2005).
72. Feuerer, M. et al. Enrichment of memory T cells and other profound immunological changes in the bone marrow from untreated breast cancer patients. Int. J. Cancer 92, 96-105 (2001).
73. + immune T cells. Cancer Res. 58, 5439-5446 (1998).
74. Willimsky, G. & Blankenstein, T. Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature 437, 141-146 (2005).
75. Marches, R., Scheuermann, R. H. & Uhr, J. Cancer dormancy from mice to man: a review. Cell Cycle 5, 1772-1778 (2006).
76. Allgayer, H. et al. Urokinase plasminogen activator receptor (uPA-R.): one potential characteristic of metastatic phenotypes in minimal residual tumor disease. Cancer Res. 57, 1394-1399 (1997).
77. Meng, S. et al. Circulating tumor cells in patients with breast cancer dormancy. Clin. Cancer Res. 10, 8152-8162 (2004). Provides evidence that patients with breast cancer who have been free of disease for 22 years still carry circulating tumour cells in their blood. It is proposed that an occult replicating population is present and sheds cells into the circulation, which eventually die.
78. Balic, M. et al. Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin. Cancer Res. 12, 5615-5621 (2006).
79. Riethmuller, G. & Klein, C. A. Early cancer cell dissemination and late metastatic relapse: clinical reflections and biological approaches to the dormancy problem in patients. Semin. Cancer Biol. 11, 307-311 (2001).
80. Heiss, M. M. et al. Minimal residual disease in gastric cancer: evidence of an independent prognostic relevance of urokinase receptor expression by disseminated tumor cells in the bone marrow. J. Clin. Oncol. 20, 2005-2016 (2002).
81. Meng, S. et al. uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues. Proc. Natl Acad. Sci. USA 103, 17361-17365 (2006). Provides evidence that circulating tumour cells and tumour tissues from patients with cancer display co-amplification of uPAR and ERBB2.
82. Moody, S. E. et al. Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis. Cancer Cell 2, 451-461 (2002).
83. Felsher, D. W. & Bishop, J. M. Reversible tumorigenesis by MYC in hematopoietic lineages. Mol. Cell 4, 199-207 (1999).
84. Gestl, S. A., Leonard, T. L., Biddle, J. L., Debies, M. T. & Gunther, E. J. Dormant wnt-initiated mammary cancer can participate in reconstituting functional mammary glands. Mol. Cell. Biol. 27, 195-207 (2007).
85. Chaurasia, P. et al. A region in urokinase plasminogen receptor domain III controlling a functional association with alpha5beta1 integrin and tumor growth. J. Biol. Chem. 281, 14852-14863 (2006).
86. Hoyer-Hansen, G. et al. Urokinase-catalysed cleavage of the urokinase receptor requires an intact glycolipid anchor. Biochem. J. 358, 673-679 (2001).
87. Shen, Q. et al. Endothelial cells stimulate self-renewal and expand neurogenesis of neural stem cells. Science 304, 1338-1340 (2004).
88. Tumbar, T. et al. Defining the epithelial stem cell niche in skin. Science 303, 359-363 (2004).
89. Pelayo, R. et al. Cell cycle quiescence of early lymphoid progenitors in adult bone marrow. Stem Cells 24, 2703-2713 (2006).
90. Talpaz, M. et al. Persistence of dormant leukemic progenitors during interferon-induced remission in chronic myelogenous leukemia. Analysis by polymerase chain reaction of individual colonies. J. Clin. Invest. 94, 1383-1389 (1994).
91. Kitzis, A. et al. Persistence of transcriptionally silent BCR-ABL rearrangements in chronic myeloid leukemia patients in sustained complete cytogenetic remission. Leuk. Lymphoma 42, 933-944 (2001).
92. Naumov, G. N. et al. Ineffectiveness of doxorubicin treatment on solitary dormant mammary carcinoma cells or late-developing metastases. Breast Cancer Res. Treat. 82, 199-206 (2003). Provides evidence that solitary non-dividing dormant tumour cells are resistant to chemotherapy.
93. Schmidt, M. et al. Differential roles of p21(Waf1) and p27(Kip1) in modulating chemosensitivity and their possible application in drug discovery studies. Mol. Pharmacol. 60, 900-906 (2001).
94. Weaver, V. M. et al. beta4 integrin-dependent formation of polarized three-dimensional architecture confers resistance to apoptosis in normal and malignant mammary epithelium. Cancer Cell 2, 205-216 (2002).
95. Fu, Y., Li, J. & Lee, A. S. GRP78/BiP inhibits endoplasmic reticulum BIK and protects human breast cancer cells against estrogen starvation-induced apoptosis. Cancer Res. 67, 3734-3740 (2007).
96. Lee, E. et al. GRP78 as a novel predictor of responsiveness to chemotherapy in breast cancer. Cancer Res. 66, 7849-7853 (2006).
97. Pootrakul, L. et al. Expression of stress response protein Grp78 is associated with the development of castration-resistant prostate cancer. Clin. Cancer Res. 12, 5987-5993 (2006).
98. Scharenberg, C. W., Harkey, M. A. & Torok-Storb, B. The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors. Blood 99, 507-512 (2002).
99. Dean, M., Fojo, T. & Bates, S. Tumour stem cells and drug resistance. Nature Rev. Cancer 5, 275-284 (2005).
100. Hirschmann-Jax, C. et al. A distinct quot;side populationquot; of cells with high drug efflux capacity in human tumor cells. Proc. Natl Acad. Sci. USA 101, 14228-14233 (2004).
101. Roepman, P. et al. An expression profile for diagnosis of lymph node metastases from primary head and neck squamous cell carcinomas. Nature Genet. 37, 182-186 (2005).
102. Weinstein, I. B. Cancer. Addiction to oncogenes - the Achilles heal of cancer. Science 297, 63-64 (2002).
103. Vessella, R. L., Pantel, K. & Mohla, S. Tumor cell dormancy: an NCI workshop report. Cancer Biol. Ther. 6(2007).
104. Beausejour, C. M. et al. Reversal of human cellular senescence: roles of the p53 and p16 pathways. EMBO J. 22, 4212-4222 (2003).
105. Collado, M. & Serrano, M. The power and the promise of oncogene-induced senescence markers. Nature Rev. Cancer 6, 472-476 (2006).
106. Xue, W. et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445, 656-660 (2007).
107. Sarkisian, C. J. et al. Dose-dependent oncogeneinduced senescence in vivo and its evasion during mammary tumorigenesis. Nature Cell Biol. 9, 493-505 (2007).
108. Roninson, I. B. Tumor cell senescence in cancer treatment. Cancer Res. 63, 2705-2715 (2003).
109. Zetterberg, A. & Larsson, O. Kinetic analysis of regulatory events in G1 leading to proliferation or quiescence of Swiss 3T3 cells. Proc. Natl Acad. Sci. USA 82, 5365-5369 (1985).
110. Zhang, J. et al. PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention. Nature 441, 518-522 (2006).
111. Coller, H. A., Sang, L. & Roberts, J. M. A new description of cellular quiescence. PLoS Biol. 4, e83 (2006). A comprehensive gene-profiling analysis of quiescence programmes induced by three different stimuli.
112. Larsson, O., Zetterberg, A. & Engstrom, W. Cell-cycle-specific induction of quiescence achieved by limited inhibition of protein synthesis: counteractive effect of addition of purified growth factors. J. Cell Sci. 73, 375-387 (1985).
113. Wang, J. & Kim, S. K. Global analysis of dauer gene expression in Caenorhabditis elegans. Development 130, 1621-1634 (2003).
114. Koornneef, M., Bentsink, L. & Hilhorst, H. Seed dormancy and germination. Curr. Opin. Plant Biol. 5, 33-36 (2002).
115. Pinkston, J. M., Garigan, D., Hansen, M. & Kenyon, C. Mutations that increase the life span of C. elegans inhibit tumor growth. Science 313, 971-975 (2006).
116. Kondo, M. et al. The p38 signal transduction pathway participates in the oxidative stress-mediated translocation of DAF-16 to Caenorhabditis elegans nuclei. Mech. Ageing Dev. 126, 642-647 (2005).
117. Fukuyama, M., Rougvie, A. E. & Rothman, J. H. C. elegans DAF-18/PTEN mediates nutrient-dependent arrest of cell cycle and growth in the germline. Curr. Biol. 16, 773-779 (2006).
118. Long, X. et al. TOR deficiency in C. elegans causes developmental arrest and intestinal atrophy by inhibition of mRNA translation. Curr. Biol. 12, 1448-1461 (2002).
119. Solomon, A. et al. Caenorhabditis elegans OSR-1 regulates behavioral and physiological responses to hyperosmotic environments. Genetics 167, 161-170 (2004).
120. Merlo, L. M., Pepper, J. W., Reid, B. J. & Maley, C. C. Cancer as an evolutionary and ecological process. Nature Rev. Cancer 6, 924-935 (2006).
121. Kitano, H. Cancer as a robust system: implications for anticancer therapy. Nature Rev. Cancer 4, 227-235 (2004). Suggests that inducing genuine dormancy (that is, cellular dormancy) is important to prevent the tumour heterogeneity from increasing and limiting robustness of cancer as a system (that is, the ability to maintain stable functioning despite perturbations, such as therapy).
122. Viswanathan, M., Kim, S. K., Berdichevsky, A. & Guarente, L. A role for SIR-2.1 regulation of ER stress response genes in determining C. elegans life span. Dev. Cell 9, 605-615 (2005).
123. Matheu, A. et al. Delayed ageing through damage protection by the Arf/p53 pathway. Nature 448, 375-379 (2007).
124. Naumov, G. N., MacDonald, I. C., Chambers, A. F. & Groom, A. C. Solitary cancer cells as a possible source of tumour dormancy? Semin. Cancer Biol. 11, 271-276 (2001).
125. Shachaf, C. M. et al. MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature 431, 1112-1117 (2004).
126. Dawson, D. W. et al. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 285, 245-248 (1999).
127. Kvalheim, G., Naume, B. & Nesland, J. M. Minimal residual disease in breast cancer. Cancer Metastasis Rev. 18, 101-108 (1999).
128. Merrie, A. E., Yun, K., van Rij, A. M. & McCall, J. L. Detection and significance of minimal residual disease in colorectal cancer. Histol. Histopathol. 14, 561-569 (1999).
129. Gath, H. J. & Brakenhoff, R. H. Minimal residual disease in head and neck cancer. Cancer Metastasis Rev. 18, 109-126 (1999).
130. Cheung, I. Y., Feng, Y., Vickers, A., Gerald, W. & Cheung, N. K. Cyclin D1, a novel molecular marker of minimal residual disease, in metastatic neuroblastoma. J. Mol. Diagn. 9, 237-241 (2007).
131. Roberts, W. M. et al. Measurement of residual leukemia during remission in childhood acute lymphoblastic leukemia. N. Engl. J. Med. 336, 317-323 (1997).
132. Bruggemann, M., Pott, C., Ritgen, M. & Kneba, M. Significance of minimal residual disease in lymphoid malignancies. Acta Haematol. 112, 111-119 (2004).
133. Schwarzenbach, H. et al. Detection of tumor-specific DNA in blood and bone marrow plasma from patients with prostate cancer. Int. J. Cancer 120, 1465-1471 (2007).
134. Morgan, T. M., Lange, P. H. & Vessella, R. L. Detection and characterization of circulating and disseminated prostate cancer cells. Front. Biosci. 12, 3000-3009 (2007).
135. Pfitzenmaier, J. et al. The detection and isolation of viable prostate-specific antigen positive epithelial cells by enrichment: a comparison to standard prostatespecific antigen reverse transcriptase polymerase chain reaction and its clinical relevance in prostate cancer. Urol. Oncol. 25, 214-220 (2007).
136. Kienle, P. & Koch, M. Minimal residual disease in gastrointestinal cancer. Semin. Surg. Oncol. 20, 282-293 (2001).
137. Max, N. & Keilholz, U. Minimal residual disease in melanoma. Semin. Surg. Oncol. 20, 319-328 (2001).
138. Blaheta, H. J. et al. Detection of melanoma cells in sentinel lymph nodes, bone marrow and peripheral blood by a reverse transcription- polymerase chain reaction assay in patients with primary cutaneous melanoma: association with Breslow's tumour thickness. Br. J. Dermatol. 145, 195-202 (2001).
139. Hosch, S. B., Scheunemann, P. & Izbicki, J. R. Minimal residual disease in non-small-cell lung cancer. Semin. Surg. Oncol. 20, 278-281 (2001).
140. Willeke, F. & Sturm, J. W. Minimal residual disease in soft-tissue sarcomas. Semin. Surg. Oncol. 20, 294-303 (2001).